Tag: BioTime
August 2, 2018
BioTime to Receive $43 Million From Juvenescence
BioTime (NYSE:BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced a new strategic alignment between AgeX Therapeutics and Juvenescence... October 20, 2016
BioTime to Present OpRegen® Clinical Trial Data at ISOPT Clinical Symposium
BioTime, a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the... June 16, 2016
BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the... June 10, 2016
BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on... February 17, 2016
Asterias Biotherapeutics Announces Intention to Distribute 3.15 Million Warrants
Asterias Biotherapeutics, Inc. (NYSEMKT:AST) simplified its capital structure through the previously announced Asset Swap with BioTime, Inc. In conjunction with... December 30, 2015
Stock of BioTime Subsidiary to Begin Trading on the NYSE MKT
BioTime, Inc. (NYSE MKT:BTX) has reported that the common stock of subsidiary OncoCyte Corporation will start trading on a "when-issued"... December 11, 2015
